Talis Biomedical Corp TLIS shares are trading higher by 30% to $7.03 Tuesday morning after the company announced it is exploring strategic options to boost shareholder value due to current market conditions.
What Happened?
Talis Biomedical formed a special committee to consider various alternatives like financing, mergers or asset divestiture. To cut costs, the company is reducing its workforce by 90% and consolidating operations in Chicago.
Despite this, revenue decreased significantly in third-quarter 2023 compared to the same period last year, but operating expenses and net losses have also decreased. They've disclosed cash reserves of $88.0 million as of September 30.
As they evaluate options, Talis Biomedical won't hold a conference call to discuss their third-quarter results. Further details can be found in their Quarterly Report on Form 10-Q for third-quarter, 2023.
See Also: Fisker Stock Is Tumbling Tuesday: What's Going On?
According to data from Benzinga Pro, TLIS has a 52-week high of $9.75 and a 52-week low of $4.35.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
